drugset / Trial / NCT00836004

Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions

NCT00836004

Phase 1 Completed 24 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to compare the rate and extent of absorption of clindamycin 300 mg capsules (test) versus Cleocin HCl (reference, administered as 1 x 300 mg capsule under fed conditions.

Timeline

Start
2003-11
Primary completion
2003-11
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Clindamycin Unknown 300 mg

Indications

No indication recorded.